Zobrazeno 1 - 10
of 17
pro vyhledávání: '"GINA ZHANG"'
Publikováno v:
Journal of Diabetes Science and Technology. 17:302-313
Introduction: Automated insulin delivery (AID) has become a well-known research topic devoted to achieving better glycemic outcomes. AID systems consist primarily of three components: the continuous glucose monitoring system, the insulin delivery sys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e591a09ea16da4b20ca8a2b22e34202
https://doi.org/10.1177/19322968221145731
https://doi.org/10.1177/19322968221145731
Autor:
Ron Brazg, Satish K. Garg, Anuj Bhargava, James R. Thrasher, Kashif Latif, Bruce W. Bode, Timothy S. Bailey, Barry S. Horowitz, Arvind Cavale, Yogish C. Kudva, Kevin B. Kaiserman, George Grunberger, John Chip Reed, Sarnath Chattaraj, Gina Zhang, John Shin, Vivian Chen, Scott W. Lee, Toni L. Cordero, Andrew S. Rhinehart, Robert A. Vigersky, Bruce A. Buckingham
Publikováno v:
Diabetes Technology & Therapeutics. 24:535-543
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d493aa6d945bb577624a173de2c28f6b
https://doi.org/10.1089/dia.2021.0540
https://doi.org/10.1089/dia.2021.0540
Publikováno v:
Journal of diabetes science and technology.
Continuous subcutaneous insulin infusion (CSII, or insulin pump) and continuous glucose monitoring (CGM) sensors have been increasingly used and associated with improved glycemic control by people with type 1 diabetes and insulin-requiring type 2 dia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::893e7fef8ec7bdcaba42f3129c9b091d
https://pubmed.ncbi.nlm.nih.gov/35876264
https://pubmed.ncbi.nlm.nih.gov/35876264
Publikováno v:
Diabetes. 71
Objective: The wear duration of insulin infusion sets (IIS) is impacted by initial local trauma caused by cannula insertion and sustained inflammation due mostly to insulin infusion, both of which affect insulin absorption. Efforts have been made to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6c170d11de7d11f0b169f9aecdbf28a
https://doi.org/10.2337/db22-784-p
https://doi.org/10.2337/db22-784-p
Publikováno v:
Diabetes. 71
Objective: Medtronic Mio™ 30 infusion set (M30IS) is a single-use consumable for pump users with pre-loaded inserter, utilizing a 30° insertion angle, and labeled for 3-day use. The M30IS wear duration is impacted by initial local trauma caused by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1dae1cc34e58efc4f95e3f94c9fa9325
https://doi.org/10.2337/db22-788-p
https://doi.org/10.2337/db22-788-p
Autor:
Gina Zhang, Barry Horowitz, Ronald L. Brazg, Anuj Bhargava, Satish K. Garg, Yogish C. Kudva, Suiying Huang, Robert Vigersky, Arvind Cavale, George Grunberger, Timothy S. Bailey, Sarnath Chattaraj, Bruce A. Buckingham, John Shin, Vivian Chen, Kevin B Kaiserman, James Thrasher
Publikováno v:
Diabetes. 70
Objective: Most insulin infusion sets (ISs) are labeled for 2- or 3-days use. The Medtronic EWIS is designed to increase wear time up to 7 days. This study reports on EWIS survival and performance during the pivotal trial (ClinicalTrials.gov: NCT0411
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d326dd40f23fa21e724e152827fad1c
https://doi.org/10.2337/db21-100-lb
https://doi.org/10.2337/db21-100-lb
Publikováno v:
Diabetes. 70
Objective: A combination insulin infusion and glucose-sensing device will dramatically improve the ease of use for automated insulin delivery systems. The objective of this preclinical study was to collect safety and efficacy data during 7-day wear o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d79a3269c725a6a70c629af1f354f8a3
https://doi.org/10.2337/db21-692-p
https://doi.org/10.2337/db21-692-p
Autor:
Vivian Chen, Kevin B Kaiserman, James Thrasher, Anuj Bhargava, Suiying Huang, Barry Horowitz, Bruce A. Buckingham, John Shin, George Grunberger, Gina Zhang, Satish K. Garg, Ronald L. Brazg, Timothy S. Bailey, Arvind Cavale, Robert Vigersky, Sarnath Chattaraj, Yogish C. Kudva
Publikováno v:
Diabetes. 70
Objective: Most insulin infusion sets (ISs) are labeled for 2- or 3-days use. The Medtronic EWIS is designed to increase wear time up to 7 days, and demonstrated a 74.8% survival rate (77.8%, excluding inadvertent early removal) in the pivotal trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1782e8527536b4b5d263d12dc549e2d6
https://doi.org/10.2337/db21-101-lb
https://doi.org/10.2337/db21-101-lb
The purpose of this article is to compare the insulin cost-savings of the Medtronic Extended Infusion Set (or EIS, a.k.a. Extended Wear Infusion Set) designed and labeled for up to 7-day use with rapid-acting insulins to the current standard of care,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f5e5ecf78ccf18f312a00ef58c93b6b
Publikováno v:
Diabetes. 69
Objective: Develop a test methodology for evaluating the reason for infusion set (IS) failure in persons with diabetes using insulin pump therapy (Continuous Sub-cutaneous Insulin Infusion, CSII). Insulin stability (physical, chemical, and microbiolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::722720a63c2f563f3f1594abad06b124
https://doi.org/10.2337/db20-1012-p
https://doi.org/10.2337/db20-1012-p